Christina Applegate says MS symptoms landed her in hospital over 30 times: What is multiple sclerosis?
Christina Applegate opened up about her battle with multiple sclerosis, revealing she has been hospitalized over 30 times in ...
Johns Hopkins Medicine1d
Baltimore Student-Athlete Is Winning Match Against Multiple Sclerosis
Gabryelle “Gabby” Scholfield, a 16-year-old student-athlete at Edmondson Westside High School in Baltimore, who plays center ...
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosis
The trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.
El Paso woman creates support network for MS patients lacking local specialists
Video Quality Speed 00:00 03:59 El Paso woman creates support network for MS patients lacking local specialists Her efforts ...
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
If approved, SNY's tolebrutinib will be the first therapy to target smoldering neuroinflammation, a key driver of disability ...
Pharmabiz2d
US FDA accepts for priority review Sanofi’s regulatory submission of tolebrutinib for patients with multiple sclerosis
US FDA accepts for priority review Sanofi’s regulatory submission of tolebrutinib for patients with multiple sclerosis: Paris Wednesday, March 26, 2025, 09:00 Hrs [IST] The US F ...
Multiple Sclerosis News Today2d
Fatigue significantly contributes to impaired well-being in MS: Study
Nearly 50% of MS patients report pronounced fatigue, which has a significantly negative impact on their well-being, a Finnish ...
En Pareja on MSN2d
What is Multiple Sclerosis? The Condition Yolanda Andrade is Battling
After much speculation about her health, it has been revealed that Yolanda Andrade is dealing with multiple sclerosis. So, ...
Applied Clinical Trials Online2d
Results of Phase III HERCULES, GEMINI 1 and 2 Trials Lead to FDA Priority Review for Tolebrutinib for Non-Relapsing Secondary Progressive MS
FDA grants Priority Review status to Sanofi's tolebrutinib for the treatment of non-relapsing secondary progressive multiple ...
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
This Phase 2 trial aims to assess the safety, tolerability, and foralumab’s effect on microglial activation in patients with na-SPMS. Intranasal foralumab offers a novel approach to potentially ...
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
NEW YORK, March 25, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
PharmiWeb2d
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and to ...